ASH 2022 | Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights how the presence of TP53 mutation and deletion 17p can lead to resistance to chemoimmunotherapy, hence chemoimmunotherapy should not be considered for patients with chronic lymphocytic leukemia (CLL) who harbor these specific genetic alterations. Dr Jain comments on results from a study that indicated that time-limited therapies, such as venetoclax plus obinutuzumab, may not be as durable in patients with these particular mutations. Dr Jain believes that, in these scenarios, long-term use of bruton’s tyrosine kinase (BTK) inhibitors may be of benefit. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Aprea Therapeutics: Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel Support, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Other: Travel Support, Research Funding; TransThera Sciences: Research Funding; Fate Therapeutics: Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Research Funding; Ipsen: Honoraria; Loxo Oncology: Research Funding; Medisix: Research Funding; Takeda: Research Funding; Precision Biosciences: Consultancy, Honoraria, Other: Travel Support, Research Funding; Servier Pharmaceuticals LLC: Research Funding; ADC Therapeutics: Research Funding; BMS: Consultancy, Honoraria, Other: Travel Support, Research Funding; Pfizer: Research Funding; Incyte Corporation: Research Funding; Cellectis: Honoraria, Research Funding; Dialectic Therapeutics: Research Funding; Novalgen: Research Funding; Newave: Research Funding; MEI Pharma: Honoraria; TG Therapeutics: Honoraria; Beigene: Honoraria; Cellectis: Honoraria, Research Funding; Mingsight: Research Funding; Pharmacyclics, Inc.: Consultancy, Honoraria, Other: Travel Support, Research Funding; Janssen Pharmaceuticals, Inc.: Consultancy, Honoraria, Other: Travel Support; Genentech, Inc.: Consultancy, Honoraria, Other: Travel Support, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: Travel Support, Research Funding; CareDx: Honoraria. Thompson: AbbVie, Gilead, Janssen, Pharmacyclics, Adaptive Biotechnologies, Genentech, Amgen: Honoraria; AbbVie, Gilead, Janssen, Pharmacyclics, Adaptive Biotechnologies, Genentech: Consultancy; Adaptive Biotechnologies: Membership on an entity’s Board of Directors or advisory committees; AbbVie, Pharmacyclics, Adaptive Biotechnologies, Genentech: Research Funding.
